What did Zhang Xinmin say Favipiravir improved in patients?

Question

Accepted Answer

Zhang Xinmin Stated Favipiravir Showed Efficacy in Coronavirus Patients

Zhang Xinmin, an official from China’s Science and Technology Ministry, stated that Favipiravir has demonstrated effectiveness in aiding coronavirus patients' recovery without apparent side effects. Clinical trials conducted in Shenzhen involving 80 participants indicated that patients receiving Favipiravir experienced enhanced chest improvement and a reduced time to test negative for the virus's genomic trace when compared to those who did not receive the drug.
Clinical Trial Results in Shenzhen

A specific clinical trial in Shenzhen, which included 80 participants, provided data suggesting positive outcomes for Favipiravir. Patients administered the drug exhibited greater improvement in their chest condition. Furthermore, these individuals achieved negative test results for the genomic trace of the virus more rapidly than the control group.
Absence of Obvious Side Effects

A key aspect of Zhang Xinmin's statement highlighted the drug's safety profile. He indicated that Favipiravir was found to be effective in helping coronavirus patients recover and that no obvious side effects were observed during its use in this context. This suggests a favourable balance between therapeutic benefit and tolerability.
Background of Favipiravir

Favipiravir, also known by the brand name Avigan, was originally developed by Fujifilm Toyama Chemical Co Ltd. It received approval for use in Japan in 2014. The drug has previously been supplied by the Japanese government as emergency aid, notably during the 2016 Ebola virus outbreak in Guinea, underscoring its use in combating viral diseases.

Reading history

Hide →

This history is cleared when the page is closed.

What did Zhang Xinmin say Favipiravir improved in patients?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends